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Conclusions: In this unscreened European population of men 
with low risk prostate cancer, outcomes were better in the 
under the age of 60 cohort. Younger age should not be 
considered a contraindication for brachytherapy as opposed 
to surgery  
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Purpose/Objective: Stereotactic Body Radiation Therapy 
(SBRT) is emerging as a promising modality treatment in the 
management of genitourinary malignancies. The delivery of 
very high radiation doses in few fractions with a steep dose 
gradient may improve the therapeutic ratio in the treatment 
of prostate cancer. In this phase II study we tested the 
efficacy and the impact on toxicity of SBRT in patients with 
low or intermediate risk prostate cancer. 
Materials and Methods: Patients with low or intermediate 
risk prostate cancer histologically confirmed were enrolled in 
this phase II study. The treatment schedule was 35 Gy in 5 
fractions on alternate days, delivered with RapidArc in FFF 
modality. Toxicity was defined according to CT-CAE criteria 
v3.0 and classified as acute if occurring within 90 days from 
treatment and as late after 90 days. Patient-reported quality 
of life (QOL) relative to urinary, sexual and gastrointestinal 
symptoms was evaluated through EPIC questionnaires. 
Results: Between January 2012 and March 2014 73 patients 
were enrolled (46 low risk, 27 intermediate risk). At a median 
follow up of 18 months (range 3-30 months) all patients 
experienced a complete biochemical response. Acute toxicity 
was mild; only 8 % of patients presented a rectal G2-toxicity, 
while a maximum G2-GU toxicity was recorded in 43% of 
patients, mainly represented by urgency, dysuria and 
stranguria. Regarding late toxicity, a G1 proctitis was 
recorded in 6% of patients and a G1-GU (urgency, cystitis) in 
31%; only 1 event of G2 urinary toxicity was observed 
(transient urethral stenosis). No heavier adverse events 
occurred. EPIC questionnaires revealed a slight worsening in 
the urinary domains during treatment, with a return to 
baseline three months after treatment. No significant 
modifications in any of the other domains explored were 
reported. 
Conclusions: Stereotactic Body Radiotherapy appears to be 
an effective therapeutic option in low and intermediate risk 
prostate cancer patients, associated with a good compliance 
and tolerance of the treatment modality, and a low profile of 
late toxicity.  
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Purpose/Objective: To determine the relationship between 
acute genitourinary (GU) toxicity and dose distributions of GU 
pelvic structures in patients who received focal dose-
escalation IMRT for localized prostate cancer. To develop a 
methodology of assessing planned dose to the bladder trigone 
using dose surface maps (DSM).  
Materials and Methods: 50 patients with intermediate/high 
risk localized prostate cancer underwent radiotherapy (RT) 
within a prospective study (DELINEATE, ISRCTN04483921) 
which involved image-guided IMRT of 74Gy/37# to the 
prostate and 82Gy/37# to the dominant intra-prostatic 
nodule. The whole bladder and catheterized urethra were 
prospectively delineated. A bladder trigone surrogate 
structure was retrospectively contoured as a triangle-shaped 
region between the transition of the urethra into the bladder 
wall caudally and the transition of the ureters in the bladder 
cranially. Axially, the posterior of the contour described the 
extent of the bladder trigone. The contour was expanded 
anteriorly from the bladder wall (Fig. 1 red contour). A copy 
of this structure was created and the contour enlarged 
anteriorly and laterally only (Fig. 1 green contour). DSM were 
generated for both structures using dosimetric analysis 
software, VODCA (MSS GmBH, Hagendorn, CH). A subtraction 
method was developed using MATLAB (Mathworks, Natwick, 
MA) to establish the dosimetric region of coincidence 
between the two DSMs, defining the bladder trigone surface 
(Fig. 1c). Cumulative dose surface histograms (DSH) were 
generated for bladder trigone (BT). In addition, whole 
bladder (WB) DSH and DVH for urethra were created in 
VODCA. 
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Acute toxicity was defined as up to 18 weeks from the start 
of RT and was assessed using the modified RTOG toxicity 
criteria weekly during RT and then at week 10, 12 and 18. 
The NCI CTCAE v4 scoring system was used pre-RT and at 
week 18. Patients were also asked to complete IPSS 
questionnaires at these times. Peak toxicity grade (G) was 
dichotomized: modified RTOG G0&1 (n=13) vs G2&3 (n=37) 
and NCI CTCAE v4 (G0 vs G1&2). The Mann Whitney U test 
was used to compare toxicity groups using a range of 
dosimetric descriptors for each GU pelvic structure. Data was 
analysed in SPSS, v22 (IBM SPSS, Armonk, NY). 
 
Results: 36 patients (72%) experienced a peak G2 RTOG acute 
toxicity and 1 patient G3. At week 18, half of the patients 
had no toxicity according to the NCI CTCAE v4. IPSS median 
and IQR at pre-RT and 18 weeks (n=45) were 5 (4-9) and 7 (5-
9) respectively.  
There were statistically significant differences in a number of 
dose surface parameters for WB and BT using NCI CTCAE v4. 
No urethral dose parameters related to toxicity (Table 1). 
There were no statistically significant results for RTOG peak 
toxicity.  
 
Conclusions: Our technique to produce the dose surface map 
of the BT has enhanced the dosimetric information available 
for analysis of acute GU toxicity. The results suggest that 
modifying dose surface parameters to WB and BT may impact 
on the incidence of acute toxicity.  
   
PO-0737   
Adjuvant hormone therapy in intermediate-high risk 
prostate cancer: LH-RH agonist versus anti-androgens 
J. Capuccini1, G. Macchia2, L. Giaccherini1, M. Zompatori3, G. 
Nuzzo2, G.C. Mattiucci4, M. Ntreta1, F. Deodato2, V. 
Valentini4, A.G. Morganti1 
1Policlinico Universitario S. Orsola Malpighi, Radiotherapy 
Department, Bologna, Italy  
2Fondazione Giovanni Paollo II Catholic University of Sacred 
Heart, Radiotherapy Department, Campobasso, Italy 
3Policlinico Universitario S. Orsola Malpighi, Radiology 
Department, Bologna, Italy  
4Catholic University of Sacred Heart, Radiation Oncology 
Unit, Roma, Italy  
 
Purpose/Objective: Adjuvant hormonal therapy (AHT) 
improves the prognosis in intermediate-high risk prostate 
cancer treated with radiotherapy (RT). Luteinizing hormone-
releasing hormone(LH -RH) agonist represent the standard 
AHT, although this treatment is associated with several 
adverse effect. An alternative treatment, not based on 
pharmacological castration, might be represented by high-
dose antiandrogens (bicalutamide 150 mg / day). However, 
data comparing this treatments in terms of disease control 
are lacking. Therefore, aim of this study was to compare the 
results of two groups of patients who underwent AHT with 
LH- RH analogues or with bicalutamide, respectively. 
Materials and Methods: We analyzed data from three 
different clinical trials in which patients received 
radiotherapy (RT) and AHT with LH- RH agonist or high doses 
bicalutamide. The therapeutic choice was based on the 
urologist and/or patient preferences. Biochemical 
recurrence-free survival (according to Phoenix criteria), local 
control, disease- free and overall survival were assessed using 
the Kaplan-Meier method. Survival curves were compared by 
log-rank test ( univariate analysis ) and Cox's Proportional 
Hazard Method (multivariate analysis , considering as 
covariates : stage , pretreatment Prostate Specific Antigen, 
Gleason Score, duration of AHT, RT doses delivered to the 
pelvic lymph nodes). Patients were classified according to 
the National Comprehensive Cancer Network 2014 risk. 
Results: A total of 315 patients were included in the analysis. 
The 5 year results at univariate analysis are reported in the 
table.Multivariate analysis confirmed the lack of impact of 
type of AHT on biochemical recurrence -free survival (p= 
0.758). 
Conclusions: 
The results of this study showed no significant differences in 
terms of biochemical and clinical outcomes among patients 
undergoing adjuvant AHT with LH -RH agonist or 
antiandrogen. Based on the lower toxicity profile of 
antiandrogens , further prospective studies comparing these 
two therapeutic alternatives appear justified.  
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